Improving immunogenicity and effectiveness of influenza vaccine in older adults

Inactivated Influenza Vaccines

(2011) Valentina Parodi et al.   DRUGS & AGING

MF59 adjuvant: the best insurance against influenza strain diversity

(2011) Derek T O’Hagan et al.   Expert Review of Vaccines

Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial

(2011) Stéphane Heijmans et al.   JOURNAL OF INFECTIOUS DISEASES

Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine

(2011) Wilbur H. Chen et al.   VACCINE

Dysregulation of human Toll-like receptor function in aging

(2010) Albert C. Shaw et al.   AGEING RESEARCH REVIEWS

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine

(2010) Seth J Sullivan et al.   Expert Review of Vaccines

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Age-Associated Decrease in TLR Function in Primary Human Dendritic Cells Predicts Influenza Vaccine Response

(2010) Alexander Panda et al.   JOURNAL OF IMMUNOLOGY

The Role of Epigenetics in Aging and Autoimmunity

(2009) Annabelle Grolleau-Julius et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood

(2009) Yu Jing et al.   HUMAN IMMUNOLOGY

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

B-cell diversity decreases in old age and is correlated with poor health status

(2008) Kate L. Gibson et al.   AGING CELL

A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses

(2008) Benoit Baras et al.   Influenza and Other Respiratory Viruses

Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus

(2008) Eric J. Yager et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study

(2008) Michael L Jackson et al.   LANCET

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice

(2008) Andreas Wack et al.   VACCINE

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE